Therapeutic Advances in Movement Disorders.
作者信息
Tanner Caroline M, Ostrem Jill L
机构信息
Movement Disorder and Neuromodulation Center, Department of Neurology, Weill Institute for Neuroscience, University of California San Francisco, San Francisco, CA, USA.
Parkinson's Disease Research, Education and Clinical Center, San Francisco Veterans Affairs Medical Care System, San Francisco, CA, USA.
出版信息
Neurotherapeutics. 2020 Oct;17(4):1325-1330. doi: 10.1007/s13311-020-00988-2. Epub 2021 Jan 15.
Abstract
摘要
相似文献
1
Therapeutic Advances in Movement Disorders.运动障碍的治疗进展
Neurotherapeutics. 2020 Oct;17(4):1325-1330. doi: 10.1007/s13311-020-00988-2. Epub 2021 Jan 15.
2
Chronic deep brain stimulation for movement disorders.用于运动障碍的慢性深部脑刺激
Adv Tech Stand Neurosurg. 1999;25:61-136; discussion 136-8. doi: 10.1007/978-3-7091-6412-9_3.
3
Clinical management of spasticity.痉挛的临床管理
J Neurol Neurosurg Psychiatry. 2005 Apr;76(4):459-63. doi: 10.1136/jnnp.2004.035972.
4
Thalamic stimulation in movement disorders.运动障碍中的丘脑刺激
J Neurosurg. 1997 Apr;86(4):737. doi: 10.3171/jns.1997.86.4.0737.
5
Deep brain stimulation for movement disorders.用于运动障碍的深部脑刺激
Neurol Res. 2004 Jan;26(1):9-20. doi: 10.1179/016164104773026480.
6
Immediate versus delayed electrical stimulation boosts botulinum toxin effect: A pilot study.即时电刺激与延迟电刺激增强肉毒杆菌毒素效果：一项初步研究。
Mov Disord. 2011 Aug 1;26(9):1784-5. doi: 10.1002/mds.23678. Epub 2011 Apr 29.
7
New treatments for movement disorders?运动障碍的新疗法？
Trends Pharmacol Sci. 1996 Oct;17(10):339-42. doi: 10.1016/s0165-6147(96)30018-7.
8
Thalamic stimulation for control of movement disorders.丘脑刺激用于控制运动障碍。
Appl Neurophysiol. 1983;46(1-4):107-11. doi: 10.1159/000101248.
9
Coding for the use of botulinum toxin for movement disorders.肉毒杆菌毒素用于运动障碍的编码。
Continuum (Minneap Minn). 2013 Oct;19(5 Movement Disorders):1406-15. doi: 10.1212/01.CON.0000436164.71565.c5.
10
Mesothalamic brain stimulation for movement disorders (functional ablation of mini-discharge circuits).中丘脑脑刺激治疗运动障碍（微小放电回路的功能性消融）
Pavlov J Biol Sci. 1987 Jan-Mar;22(1):40.
引用本文的文献
1
Intrathecal tocilizumab for immune-mediated central nervous system complication after haploidentical hematopoietic stem cell transplantation in children: Two case reports.鞘内注射托珠单抗治疗儿童单倍体造血干细胞移植后免疫介导的中枢神经系统并发症：两例报告
Heliyon. 2024 Nov 13;10(22):e40356. doi: 10.1016/j.heliyon.2024.e40356. eCollection 2024 Nov 30.
本文引用的文献
1
Palliative Care for Parkinson's Spectrum Disorders: an Emerging Approach.帕金森综合征障碍的姑息治疗：一种新兴方法。
Neurotherapeutics. 2020 Oct;17(4):1456-1463. doi: 10.1007/s13311-020-00989-1. Epub 2021 Jan 13.
2
Treatment of Disorders of Tone and Other Considerations in Pediatric Movement Disorders.儿科运动障碍的肌张力障碍及其他相关问题的治疗。
Neurotherapeutics. 2020 Oct;17(4):1713-1723. doi: 10.1007/s13311-020-00984-6. Epub 2021 Jan 6.
3
Approaches to Disease Modification for Parkinson's Disease: Clinical Trials and Lessons Learned.帕金森病的疾病修饰治疗方法：临床试验及经验教训。
Neurotherapeutics. 2020 Oct;17(4):1393-1405. doi: 10.1007/s13311-020-00964-w. Epub 2020 Nov 17.
4
Approach to Cognitive Impairment in Parkinson's Disease.帕金森病认知障碍的处理方法。
Neurotherapeutics. 2020 Oct;17(4):1495-1510. doi: 10.1007/s13311-020-00963-x. Epub 2020 Nov 17.
5
Overcoming Barriers to Parkinson Disease Trial Participation: Increasing Diversity and Novel Designs for Recruitment and Retention.克服帕金森病试验参与的障碍：增加多样性和新颖的招募及保留设计。
Neurotherapeutics. 2020 Oct;17(4):1724-1735. doi: 10.1007/s13311-020-00960-0. Epub 2020 Nov 4.
6
Gene and Cell-Based Therapies for Parkinson's Disease: Where Are We?基于基因和细胞的帕金森病疗法：我们在哪里？
Neurotherapeutics. 2020 Oct;17(4):1539-1562. doi: 10.1007/s13311-020-00940-4. Epub 2020 Oct 30.
7
Surgical Treatment of Parkinson's Disease: Devices and Lesion Approaches.帕金森病的手术治疗：器械与毁损方法。
Neurotherapeutics. 2020 Oct;17(4):1525-1538. doi: 10.1007/s13311-020-00939-x. Epub 2020 Oct 28.
8
Treatment of Dystonia: Medications, Neurotoxins, Neuromodulation, and Rehabilitation.治疗肌张力障碍：药物、神经毒素、神经调节和康复。
Neurotherapeutics. 2020 Oct;17(4):1622-1644. doi: 10.1007/s13311-020-00944-0. Epub 2020 Oct 23.
9
Modulation of the Microbiome in Parkinson's Disease: Diet, Drug, Stool Transplant, and Beyond.帕金森病中微生物组的调节：饮食、药物、粪便移植及其他。
Neurotherapeutics. 2020 Oct;17(4):1406-1417. doi: 10.1007/s13311-020-00942-2. Epub 2020 Oct 9.
10
Sleep Issues in Parkinson's Disease and Their Management.帕金森病中的睡眠问题及其管理。
Neurotherapeutics. 2020 Oct;17(4):1480-1494. doi: 10.1007/s13311-020-00938-y. Epub 2020 Oct 7.
Zotero 插件